US governors order Ebola quarantine

Medical worker isolated in New Jersey tests negative for virus

UK drugmakers show standalone strength

Record results for Shire; AstraZeneca wins backing for new drug

Progress against Aids spurs GSK float plan

Market for antiretrovirals roughly the same as that for insulin

Big pharma fights drug tardiness charge

Drug companies face ethical scrutiny on Ebola response

Industry response to Ebola quickens

Drugmakers to be offered indemnity for new vaccine

Andrew Ballheimer, Sara Pickersgill and Claire Coppel (blonde hair) from Allen & Overy. Photograph: Rosie Hallam

Three generations in one office

Millennial, Generation X and baby-boomer colleagues on their jobs

Witty goes some way to disarm gainsayers

Better news on drug pipelines still needed to pacify doubters

Mylan tweaks $5bn ‘inversion’ deal

Drugs maker pushes on with Abbott unit purchase that will cut tax rate

GSK’s chief Witty comes out fighting

Drugmaker ‘extremely pragmatic’ about options for boosting value

Ebola vaccine doses expected this year

GSK anticipates initial supply to be available in two months

GSK looks at potential float of HIV unit

Cost-cutting and multibillion-pound restructuring drive launched

Amgen: splitting hairs

A break-up would be an exercise in valuation arbitrage

Loeb urges Amgen to explore a break-up

Activist investor says the biotech company is trading at a ‘substantial discount’ to its peers

A modern plague spread by love and fear

Vaccines and drugs are unlikely to save west Africa from Ebola

Shire CFO jumps ship for Severn Trent

Drugs group loses executive days after breakdown of takeover deal

Valeant hints at higher bid for Allergan

Pharma group plays down talks of split with Pershing Square

AbbVie hits at Treasury as Shire deal dies

González calls for comprehensive US tax reform

UK backs unlicensed medicines bill

New drugs for terminally ill would help cure cancer, says Saatchi

To stop ‘deserters’, reform tax system

Rhetoric alone will not inspire companies to pay more in taxes

M&A deal failure at highest since 2008

A total of $573bn worth of deals have been withdrawn so far, compared with $640bn in 2008


More FT Twitter accounts